BioSyent (RX.V or BIOYF) is a rapidly growing pharmaceutical company that acquires or in-licenses proven drugs and markets them in Canada. Their business model is to build and sell a portfolio of products that have a peak penetration potential that is too small for major pharmaceutical companies. What has fascinated us about BioSyent is their ability to consistently grow revenue and earnings. In fact, their pharmaceutical sales have grown sequentially for the past 12 quarters, which is very rare in the microcap space. In 2012 they announced several new products that they have added to their portfolio plus they have a nice pipeline of additional products that we expect to further fuel their growth. In the most recent quarter they grew revenues 60% and net income 79% year/year. Listen to CEO Rene Goehrum as he tells the story.
Disclosure: Mike King is LONG BioSyent. This presentation was recorded on February 11th. All participants were not active in the stock on February 11th. The company DID NOT compensate MicroCapClub to present.
MicroCapClub Invitational Presentation Lineup and Dates:
January 3rd: Where Food Comes From (WFCF) [VIEW PRESENTATION]
January 7th: OptimizeRx (OPRX) [VIEW PRESENTATION]
January 10th: Abtech Holdings (ABHD) [VIEW PRESENTATION]
January 14th: Parametric Sound (PAMT) [VIEW PRESENTATION]
January 17th: NXT Energy (SFD.V) [VIEW PRESENTATION]
January 21st: Noble Roman’s (NROM) [VIEW PRESENTATION]
January 30th: Misonix (MSON) [VIEW PRESENTATION]
February 31st: Greystone Logistics (GLGI) [VIEW PRESENTATION]
February 13th: Vertex Energy (VTNR)
The MicroCapClub (mc2) is an exclusive microcap forum focused on microcap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded microcap investors. Our goal at MicroCapClub.com is quality membership and quality stock ideas. If you are an experienced micro cap investor, feel free to Apply today.